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In many tumors, cells transition reversibly between slow-proliferating tumor-initiating cells 
(TIC) and their differentiated, faster-growing progeny. Yet how transcriptional regulation of 
cell cycle and self-renewal genes is orchestrated during these conversions remains unclear. 
In this study, we show that as breast TIC form, a decrease in cell-cycle and increase in self-
renewal gene expression is coregulated by SOX2 and EZH2, which colocalize at CpG islands. 
This pattern was negatively controlled by a novel long non-coding RNA (lncRNA) that we 
name SCIRT, which was markedly upregulated in tumorspheres but colocalized with and 
counteracted EZH2 and SOX2 during cell cycle and self-renewal regulation to restrain 
tumorigenesis. SCIRT specifically interacted with EZH2 to increase EZH2 affinity to FOXM1 
without binding the latter. In this manner, SCIRT induced transcription at cell cycle gene 
promoters by recruiting FOXM1 through EZH2 to antagonize EZH2-mediated effects at 
target genes. Conversely, on stemness genes, FOXM1 was absent and SCIRT antagonized 
EZH2 and SOX2 activity, balancing towards repression. These data suggest that the 
interaction of a lncRNA with EZH2 can alter the affinity of EZH2 for its protein binding 
partners to regulate cancer cell state transitions.  
 
Statement of Significance 
Findings show that a novel lncRNA SCIRT counteracts breast tumorigenesis by opposing 
transcriptional networks associated with cell cycle and self-renewal.  
  




The clonal model of tumor growth has been revised by the discovery of heterogeneous, 
tissue-like organization of many cancer types (1,2). In this view, cancers form hierarchies of 
tumor-initiating cells (TICs), which give rise to differentiated cells with limited proliferative 
potential (3). TICs can self-renew, divide indefinitely and produce differentiated cells within 
the tumor mass, generating cell states that create intra-tumor heterogeneity (3). TICs are 
highly metastatic and being slow-proliferating are resistant to chemotherapy, two 
properties linked to treatment failure and relapse (4). These risks have sparked interest in 
the potential for TIC-targeting therapies. However, strategies for eliminating TIC populations 
could be complicated by the dynamic equilibrium that exists between TIC and non-TIC states 
(3), suggesting a need to target both compartments simultaneously.  
The self-renewal capacity that drives the formation and expansion of TICs has parallels to 
that in embryonic stem cells, with the involvement of pluripotency-associated transcription 
factors (TFs) such as SOX2 and chromatin modifiers such as EZH2 (5,6). Interestingly, SOX2 
and EZH2 also promote cancer cell plasticity in prostate cancer by inducing expression of 
neuroendocrine markers which promote metastasis and anti-androgen resistance (7). In 
addition, EZH2 can display oncogenic Polycomb-independent functions to regulate 
transcription through binding specific TFs (8,9).  
Certain surface markers can prospectively isolate TIC populations from tumors or cell lines 
(10). However, the specificity of these markers for TIC populations, especially in triple-
negative breast cancer (TNBC), is imperfect (11). As a result, retrospective approaches to 
enrich for TICs have been developed, which use three-dimensional (3D) culturing conditions 
and low plating densities to form clonal cultures of TIC-enriched tumorspheres (spheres) 
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(12,13). By culturing spheres, we have studied the regulatory transcriptional networks that 
drive TIC formation in breast tumors.  
While transcription factors (TFs) controlling self-renewal of TICs have been partially 
characterized (14), factors that regulate plasticity between TIC and non-TIC compartments 
remain unknown. We hypothesized that factors driving TIC formation could be counteracted 
by negative feedback loops keeping cells in a poised state to facilitate easy cell state 
transitions, with consequences for cancer treatment.  
Here we demonstrate that SOX2 and EZH2 directly repress cell-cycle gene transcription and 
activate self-renewal by recognizing CpG islands in breast cancer cells. We further show that 
a previously undescribed lncRNA counteracts these processes, affecting these regulatory 
networks by negative feedback. Further understanding the regulatory dynamics by which 
lncRNAs control cell plasticity may aid the development of novel therapies that may not only 
target the existing TICs but also prevent the dynamic conversion of TICs to non-TICs and vice 
versa. 
 
Materials and Methods  
Mammalian cell culture  
Breast cancer cell lines MDA-MB-231, MCF-7, SKBR3, T47D, MDA-MB-468, BT549, MDA-MB-
453 and BT474 were obtained from ATCC (Manassas, VA, USA). MDA-MB-231 and MCF-7 
cells were grown in Dulbecco’s Modified Eagle Medium (Sigma), SKBR3 in McCoy's 5a 
Medium Modified (Sigma), T47D and BT549 in RPMI-1640 Medium (Sigma), MDA-MB-468 
and MDA-MB-453 in Leibovitz's L-15 Medium (Sigma) and BT474 in DMEM/F12 Medium 
(Gibco), supplemented with 10% fetal calf serum, 2 mM L-glutamine, 100 U ml−1 penicillin, 
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and 100 mg ml−1 streptomycin. Between thawing and the use in the described experiments, 
the cells were passaged no more than five times. Routinely, the state of cells was checked 
for cellular morphology and compared with images from ATCC website. All cell lines were 
monthly tested for mycoplasma (MycoAlert, Lonza) and were always found negative. 
Sphere culture (tumorspheres) 
MDA-MB-231, MCF-7, SKBR3, T47D, MDA-MB-468, BT549, MDA-MB-453 and BT474 cells 
were plated in single-cell suspension in ultra-low attachment plates (Corning, # CLS3471). 
Cells were grown in serum-free DMEM/F12 medium (Gibco) supplemented with B27 (1:50, 
Gibco), 20 ng ml−1 basic fibroblast grown factor (bFGF, Biolegend) and 20 ng ml−1 
epidermal grow factor (EGF, Sigma). Tumorspheres were collected after 16 hours or after 5 
days of sphere formation. For sphere formation assay breast cancer cells were plated in 
ultra-low attachment plates at a density of 2x103 for MDA-MD-231 and 1x103 for MCF-7 
cells/well and formed spheres with a size larger than 75 μm were counted under the 
microscope. Percentage of sphere formation efficiency (SFE%) was calculated as a ratio 
between the number of formed spheres divided by the number of cells seeded, multiplied 
by 100.  
 
Transfections 
Silencer Select siRNAs were purchased from Ambion. Cells were transfected using 
Lipofectamine RNAiMAX (Invitrogen) following the manufacturer’s recommended protocol. 
Unless otherwise specified 25nM of siRNAs were transfected for 48h or 96h. siRNA 
sequences or catalog number can be found in Supplementary Table 8, sheet #1.  
RNA isolation and RT-qPCR assays 
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Total RNA from cultured cells was extracted using TRI Reagent (Sigma) following the 
manufacturer’s instructions including DNase I treatment. For gene expression, cDNA was 
synthesized from 1 μg of purified DNase-treated RNA using RevertAidTM M-MuLV reverse 
transcriptase and random hexamer primers (Thermo Scientific), according to the 
manufacturer’s protocols. qRT-PCRs were performed on a StepOne™ Real-Time PCR 
System using Fast SYBR® Green Master Mix (both from Applied Biosystems).  
We calculated the transcript copy number by using a previously published protocol 
(15,16). Briefly, RNA relative copy numbers were determined by RT-qPCR using standard 
curves and normalized to -actin levels. The primer sequences used are reported in 
Supplementary Table 8, sheet #2.  
Primary tumor preparation  
Fresh primary samples were collected from Charing Cross hospital within 1 hour of 
operating and retrieved in DMEM medium on ice. Samples were cut into pieces <1mm using 
a scalpel, washed once in DMEM medium, then proteolytically digested for 1.5-2 hours in 
5ml of medium containing proteolytic enzymes (hyaluronidase 100U/ml, collagenase 
3000U/ml). Once cells had appropriately detached from the extracellular matrix (assessed 
by checking cells under a haemocytometer), they were centrifuged at 200 x g for 10 mins at 
room temperature, with supernatant carefully removed and cells resuspended in full 
medium. Tumor cells were then sorted using Magnet Activated Cell Sorting (MACS) to 
deplete extraneous cell types, beads specific for blood cells (Lineage Depletion Kit, Human, 
MACS) and fibroblasts (fibroblast depletion kit, human, MACS).  
Protein extraction and western blotting 
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Cells were harvested in RIPA buffer (Sigma-Aldrich, St. Louis, MI) supplemented with a 
protease inhibitor cocktail (Roche Applied Science, Indianapolis, IN). Cell lysates were 
centrifuged at 14,000 rpm and the supernatant was collected. Protein lysates were 
quantified using a BCA Protein Assay Reagent kit (Pierce, Thermo Scientific, Waltham, MA). 
Fifty micrograms of lysates were resolved by SDS-PAGE and transferred to nitrocellulose 
membranes (Amersham, Piscataway, NJ). After blocking in 1X PBS containing 5% (w/v) milk 
and 0.1% Tween20 (v/v), membranes were incubated with the specific antibodies overnight 
at 4C. Membranes were then washed three times with 1X PBS containing 0.1% Tween20 
(v/v), incubated with horseradish peroxidase-conjugated goat anti-rabbit or goat anti-mouse 
antibody (Sigma-Aldrich), and washed again to remove unbound antibodies. Bound antibody 
complexes were detected with SuperSignal chemiluminescent substrate (GE Healthcare, 
Little Chalfont, UK). Antibodies used for WB can be found in Supplementary Table 8, sheet 
#6.  
Statistical analysis 
Results for continuous variables are presented as means ± standard deviation unless stated 
otherwise and significance was determined using the Mann-Whitney test using GraphPad 
Prisma 8 (GraphPad Software, La Jolla California USA) or R (https://www.r-project.org/). 
Expression values and statistical analysis for differential gene expression studies were 
performed with DESeq2 from the Bioconductor or by using GEO2R 
(https://www.ncbi.nlm.nih.gov/geo/geo2r/). Significance for overlapping genes was 
computed by using a Hypergeometric test. Significant enrichment for SCIRT binding on 
promoters was determined using CEAS (http://liulab.dfci.harvard.edu/CEAS/). Significant 
differential expression of SCIRT, FOXM1, EZH2 and SOX2 in tumor, normal and metastatic 
samples from TCGA and GTEx datasets as well as correlation analyzes were obtained by 
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applying two-sided Welch's t-test and Pearson correlation respectively and computed using 
R (https://www.r-project.org/). Logrank p-values for survival analyzes were computed with 
KMplot or cBioPortal. 
Differences were considered significant when p-values or p-adjusted-values were < 0.05. 
Accession number 
The dataset supporting the conclusions of this article is available in the Gene Expression 
Omnibus SuperSeries (GSE136195).  
 
Results 
Gene expression change during sphere formation reflects the induction of self-renewal 
and reduction of cell-cycle 
To evaluate how gene expression changes during sphere formation in aggressive breast 
cancer, we cultured TNBC MDA-MB-231 cells in adherent (adh) and sphere conditions for 16 
hours (h) and 5 days (d) and performed RNA-seq (Figure 1a and Supplementary Table 1). We 
selected MDA-MB-231 (and later MCF-7 for further validation) because these cell lines have 
been previously reported as good models to study breast cancer stem cells in a study that 
compared cell lines with primary tissues (17). We chose an early time point (16h) to 
specifically detect early gene expression changes during sphere formation without 
confounding factors, such as alterations of the geometry within the spheres or limited 
access to nutrients within the cultures. A five day time point was chosen to identify genes 
common between nascent and mature spheres. After bioinformatic analysis, we identified 
2559 and 2636 genes that were up-regulated in spheres grown for 16h and 5d respectively 
with 1482 up-regulated in common. Furthermore, we uncovered that 2344 and 2856 genes 
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were down-regulated in spheres grown for 16h and 5d respectively, whereas 1547 were 
down-regulated in common (Figure 1a and Supplementary Table 1, p-adjusted < 0.01). 
Pathways enriched for genes up- and down-regulated in spheres grown for 16h and 5d are 
shown in Supplementary Table 2. We validated top up- and down-regulated genes by RT-
qPCR (Figure S1a). As expected, transcripts coding for proteins known to be involved in stem 
cell renewal, including KLF4, NOTCH1 and TGFB1, were significantly up-regulated after 16h 
or 5d of sphere growth (Figure S1b and Supplementary Table 1, p-adjusted < 0.01), 
supporting the biological relevance of our model system and analysis. By using the Enrichr 
tool (18), we found that genes up-regulated in sphere culture at both time-points were 
significantly enriched in PI3K-Akt and TGFβ signaling pathways (Figure S1c, p-adjusted < 
0.01), compared to cells grown in adh conditions. Each pathway has been shown to induce 
breast cancer stem cell formation (19,20). Importantly, analysis of the ChEA database (21), 
using Enrichr, indicated that ZNF217, KDM2B, SOX2 were the top enriched TFs or chromatin-
modifying enzymes that bind within the promoters of observed up-regulated genes in 
spheres (Figure S1c, p-adjusted < 0.01). Each one of these factors has been identified as a 
strong regulator of breast cancer stem cell self-renewal and tumorigenesis (5,22,23). In 
summary, these results confirm that genes induced during sphere growth are enriched for 
tumorigenic pathways and regulated by tumorigenic TFs. 
Interestingly, transcripts significantly down-regulated at 16h and 5d of sphere growth were 
strongly enriched for cell-cycle promoting genes, and frequently contained binding sites of 
two master transcriptional regulators of cell-cycle, FOXM1 or E2F4, within their promoters 
(Figure S1d p-adjusted < 0.01). Overall, these effects indicate concomitant reductions of 
proliferative and increases of self-renewal gene expression in breast cancer spheres during 
the adh to sphere transition. 
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SCIRT lncRNA is up-regulated in spheres (16h and 5d) but counteracts stemness 
Next, we hypothesized that lncRNAs could regulate transcriptional dynamics observed 
during sphere formation and breast cancer tumorigenesis. To explore undescribed lncRNAs 
that could be involved in this process, we searched for long non-coding transcripts that were 
up- or down-regulated in spheres after both 16h and 5d, and displaying a degree of cross-
species conservation, using a previously established pipeline (24). Seven lncRNA candidates 
presented such characteristics (Figure 1b, p-adjusted < 0.01 ). We focused on RP5-
1120P11.1 (also annotated as LOC101929705 or AL109615.3) because it was strikingly up-
regulated in spheres (Figure 1b and Supplementary Table 1, p-adjusted < 0.01) but 
surprisingly, its depletion strongly induced sphere formation in both MDA-MB-231 and MCF-
7 breast cancer cells (Figure 1c, d), suggesting that it may act through negative feedback. 
We named this lncRNA Stem Cell Inhibitory RNA Transcript (SCIRT).  
Our RNA-seq data indicated several SCIRT isoforms including RP5-1120P11.1 (Figure S2a). To 
precisely map the TSS of SCIRT and to understand which one of these two isoforms is most 
expressed in breast cancer, we analyzed public Cap Analysis of Gene Expression sequencing 
(CAGE-seq) data from the ENCODE project (https://www.encodeproject.org/), performed in 
MCF-7 breast cancer cell lines (Figure. S2b). RP5-1120P11.1 and isoform n3 present a CAGE-
seq signal overlapping with their common TSSs in MCF-7 cells, reinforcing the hypothesis 
that the transcription of SCIRT starts from this region. Within the SCIRT locus, another 
undescribed transcript is annotated on the opposite strand of SCIRT (C6orf223), however, 
C6orf223 does not appear to be expressed in our system (Figure S2a). Next, we observed 
that SCIRT was also up-regulated in spheres derived from primary breast cancer specimens 
(Figure 2a) and several other breast cancer cell lines (Figure S2c) except BT549, maybe due 
to genetic or epigenetic defects accumulated in these cell lines. Additionally, we observed 
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that SCIRT expression levels were heterogeneous in different breast cancer cell lines (Figure 
S2c) but were significantly higher in more aggressive basal-like primary tumors compared to 
luminal breast cancer subtypes in cells derived from primary tumors (Figure 2a).  
Breast cancer cells in which SCIRT expression was depleted by two independent siRNAs 
(siRNA knockdown efficiency <90%, Figure S2d) showed increases in sphere formation over 
two passages (Figure 2b). In contrast, over-expression of SCIRT in MDA-MB-231 cells (Figure 
S2e) decreases sphere formation efficiency (Figure S2f). These results indicate that SCIRT 
RNA restrains breast cancer self-renewal capacity. Additionally, when MDA-MB-231 spheres 
with stable down-regulation of SCIRT (shSCIRT) were injected subcutaneously into the flanks 
of immunocompromised mice, tumor formation was enhanced, suggesting that SCIRT can 
also reduce breast cancer tumorigenesis in vivo (Figure 2c). SCIRT silencing also significantly 
increased directional cell migration and cell speed (Figure S3a, b), in aggregate indicating 
that SCIRT opposes breast cancer progression. 
SCIRT is a chromatin-associated lncRNA that down-regulates self-renewal genes and 
induces cell-cycle genes 
To understand the mechanism by which SCIRT opposes stemness we first looked at its 
subcellular localization (Figure 2d, e and Figure S3c, d). RNA FISH showed that SCIRT was 
exclusively located into the nucleus of MCF-7 breast cancer cells (Figure 2d) and that its 
signal was strongly reduced in cells treated with SCIRT siRNA (siSCIRT). Subcellular 
fractionation followed by RT-qPCR indicated that SCIRT mainly localizes in the chromatin-
associated compartment of spheres derived from TNBC MDA-MB-231 (Figure 2e) and MDA-
MB-468 (Figure S3c) cells. Additionally, analysis of RNA-seq from MCF-7 fractions (25) also 
showed chromatin localization of SCIRT in these cells (Figure S3b).  
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Next, to identify genes regulated by SCIRT, we performed RNA-seq from MDA-MB-231 
spheres where we depleted SCIRT using two different siRNAs. SCIRT silencing (siSCIRT#1 and 
#2 overlap) increased the expression of 653 and decreased the expression of 768 genes (p-
adjusted < 0.05, Wald Test; Figure S4a and Supplementary Table 3). Interestingly, SCIRT 
regulation of gene expression recapitulated pathway enrichment observed for genes 
modulated in spheres versus adh cells but in the opposite direction. Accordingly, genes 
induced by SCIRT (down-regulated upon SCIRT depletion) were strongly enriched in cell-
cycle-related signaling and mitosis whereas genes repressed by SCIRT (up-regulated upon 
SCIRT silencing) were strongly enriched in stem cell expansion as well as neuronal functions 
(Figure 3a and Figure S4a-c). This indicates that SCIRT silencing increases sphere formation 
(Figure 1c, d and Figure 2b) because this lncRNA acts by repressing self-renewal and by 
activating cell-cycle gene expression, operating in negative feedback to fine-tune separate 
gene expression programs.  
SCIRT globally binds to promoter or enhancer regions to increase expression of cell-cycle 
genes and decrease expression of self-renewal genes 
Since SCIRT is an abundant chromatin-associated lncRNA (Figure 2e and Figure S3c, d) with 
expression levels comparable to TFs that are active in breast cancer, such as SOX2 
(Supplementary Table 3), it may regulate gene expression by interacting with several 
specific chromatin loci. To evaluate this possibility, we performed Capture Hybridization 
Analysis of RNA targets (CHART) with DNA-sequencing (26) to identify chromatin regions 
bound by SCIRT. Pulldown with SCIRT probes showed strong enrichment (20-25-fold) of the 
SCIRT transcript compared to DNA oligonucleotides complementary to control LacZ 
sequence (from Escherichia coli, frequently used as control sequence for this kind of 
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experiment (26-28)) (Figure 3b), indicating that we enriched for specific endogenous regions 
of SCIRT. Moreover, SCIRT probes did not enrich for MALAT1 or GAPDH transcripts used as 
negative control RNAs (Figure 3b). Following CHART, we used massively parallel sequencing 
(CHART-seq) to identify all the chromatin regions that are associated with SCIRT. Similar to 
the previous experiment (Figure 3b), regions bound by SCIRT were depleted of LacZ peaks 
(Figure 3c and Figure S5a). Moreover, SCIRT chromatin binding regions show strong 
PhastCons signal (given by evolutionary conserved elements in a multiple alignment) that 
peaks at their center (Figure S5b), implying that SCIRT interacts with conserved cis-
regulative regions around the genome. Conversely, LacZ peaks do not occur at conserved 
regions (Figure S5b). By calculating the fold-change of SCIRT signal versus input control, 
followed by metagene profiling, we observed that SCIRT peaks occur in the proximity of 
transcriptional start sites (TSSs) and are depleted at transcriptional termination sites (TTSs) 
(Figure S5c). Interestingly, the highest levels of SCIRT binding, considering the ratio of 
observed over expected values, were at promoters and CpG islands (Figure S5d; p < 2.2e -
16, One-sided binomial test). Using the HOMER peak caller (29), we detected 15,999 
significant peaks for SCIRT (false discovery rate (FDR) < 0.001), which were common 
between two independent experiments (Supplementary Table 4). We observed that 12,724 
of these peaks were associated with a total of 7,130 genes, being present within 200 
kilobases (Kbs) from their TSSs (Figure 3d). We found a significant overlap between the 
genes up- or down-regulated following SCIRT depletion and the genes associated with the 
SCIRT peaks (Figure 3d, p < 2.2e -16, Hypergeometric test, 1.9-fold higher than expected by 
chance for both up-regulated and down-regulated genes), suggesting the association of 
SCIRT with chromatin as having a functional role in the regulation of those genes. Twenty-
three percent of SCIRT peaks were located within promoters of genes regulated by SCIRT, as 
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shown by co-localization with promoter-specific H3K4me3 marks (Figure S5e). Additionally, 
43% of the peaks were located within enhancers, as shown by co-localization with 
enhancer-specific H3K4me1 histone modifications (Figure S5e) and 32% in undefined 
positions. In both promoters and enhancers, SCIRT peaked exactly at the center of the valley 
formed by the histone modifications peaks (Figure S5f) indicating that it may interact with 
proteins within these locations. This indicates that SCIRT can increase or repress gene 
transcription through association with promoters or enhancers. We also observed that 
transcripts up-regulated by siSCIRT were significantly enriched for genes involved in TGFβ 
and PIK3-Akt pathways and had pluripotency factors (KDM2B, SOX2, SOX9) enriched within 
their promoters (from ChEA), (Figure 3d, bottom-right). On the other hand, transcripts 
down-regulated by siSCIRT were significantly enriched for cell-cycle and DNA replication 
pathways and had promoters that were enriched for TFs that induce cell-cycle (FOXM1, 
E2F4, E2F7) (Figure 3d, bottom-left).  
 
SCIRT interacts with EZH2 to antagonize its Polycomb-independent activity. 
By analyzing public ChIP-seq databases (ChEA), we showed that KDM2B represents the most 
enriched factor interacting significantly with the promoters of genes up-regulated by siSCIRT 
and associated with SCIRT peaks (Figure 3d bottom-right). KDM2B maintains pluripotency of 
stem cells by recruiting PRC1 to CpG islands which co-localize with PRC2 (30). Several 
studies have suggested that nuclear lncRNAs can interact with PRC2 to promote 
transcriptional gene silencing (31,32). To evaluate whether SCIRT acts through a similar 
mechanism, we performed RNA immunoprecipitation (RIP)-RT-qPCR for SCIRT, using an 
antibody recognizing the PRC2 catalytic component EZH2 as it has been shown that RNA 
preferentially binds PRC2 proximally to its methyltransferase center (33). In line with our 
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hypothesis, SCIRT is associated with EZH2 in spheres formed from both MCF-7 and MDA-
MB-231 cells (Figure S6a). We then used streptavidin-binding S1 aptamers fused to four 
SCIRT partially overlapping fragments (F1-F4) to pull down interacting proteins in vitro 
followed by immunoblotting for EZH2 protein, to evaluate the region of SCIRT where EZH2 
binds. We observed EZH2 interacts preferentially with the 5’ half of SCIRT (Figure S6b; F1 
and F2) as predicted by catRAPID (http://service.tartaglialab.com/page/catrapid_group) 
(Figure S6c and d). Based on this algorithm, EZH2 interacts with SCIRT at position 226-277 or 
626-677 (Figure S6d). Interestingly, G4hunter 
(http://bioinformatics.ibp.cz:8888/#/analyze/quadruplex) 
predicted a G-quadruplex structure at position 214-264 of SCIRT. Because it has been shown 
that EZH2 specifically binds G-quadruplex structures present on RNA transcripts (34), this 
suggests that EZH2 specifically binds SCIRT by recognizing a G4-quadruplex structure in its 5’ 
region.  
Next, to evaluate the functionality of the SCIRT-EZH2 interaction, we silenced EZH2 (siEZH2) 
and performed RNA-seq in spheres to assess whether EZH2 regulates the same transcripts 
modulated by SCIRT (Supplementary Table 3 and Supplementary Table 5). Intriguingly, a 
significant fraction of genes up-regulated by siEZH2 were also down-regulated by siSCIRT 
(Figure 4a, p < 2.2e -16, hypergeometric test; fold enrichment = 7.6) suggesting that SCIRT 
counteracts EZH2-mediated gene activation in breast TICs. In contrast, genes down-
regulated by siEZH2 significantly overlap with genes up-regulated by siSCIRT (Figure 4b, p = 
1.01e -13, hypergeometric test; fold enrichment = 4.1). These data suggest that SCIRT may 
interact directly with EZH2 to antagonize both its repressive and activating functions. Next, 
we wondered whether SCIRT would change the profile of H3K27me3, a histone mark 
associated with gene repression induced by the EZH2/PRC2 complex, on genes coregulated 
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by SCIRT and EZH2. To assess this, we performed ChIP-seq of H3K27me3 in cells growing in 
3D conditions after siSCIRT, siEZH2 or control siRNA (siNC) treatment and assessed its levels 
across all genes as well as SCIRT controlled genes, including promoters (Figure 4c-e). 
Although as expected, H3K27me3 signal was elevated throughout the bodies of genes that 
are not expressed, but absent at active genes (Figure 4c), H3K27me3 global profile did not 
change upon either siEZH2 or siSCIRT treatment (Figure 4c). More importantly, H3K27me3 
levels were low and did not change upon siSCIRT or siEZH2 treatment, either for SCIRT-
regulated genes or their promoters. (Figure 4d, e). Lack of change in H3K27me3 global levels 
following transient EZH2 inhibition is in line with previous observations (35) and it is likely 
due to compensation from EZH1 (36). Based on these results, we propose that gene 
expression change observed following siEZH2 and siSCIRT is likely to be Polycomb-
independent.  
 
SCIRT interacts with chromatin loci and acts through FOXM1, EZH2 and SOX2  
We observed that genes directly activated by SCIRT were enriched for cell-cycle and mitotic 
genes mostly controlled by FOXM1 (Figure 3d, bottom-left) and those down-regulated by 
SCIRT were enriched for self-renewal, TGFβ and PIK3-Akt signaling, transcriptionally 
controlled by SOX2 or other pluripotency controlling factors (Figure 3d, bottom-right). As it 
has been shown in adh breast cancer cells (37), we observed that FOXM1 also activates the 
expression of mitotic genes in cells growing in spheres (Figure S6e). This led us to 
hypothesize that SCIRT could increase transcription of selected cell-cycle genes by recruiting 
FOXM1 to their promoters or enhancers, counteracting the Polycomb-independent 
repression of these genes exerted by EZH2. Accordingly, depletion of EZH2 (siEZH2) in 
spheres led to an increase in the expression of cell-cycle genes that are both targets of SCIRT 
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and FOXM1 (Figure S6f). At the same time, SCIRT could decrease transcription of self-
renewal genes by forming a complex with EZH2 and SOX2 and counteracting their activating 
effect on those promoters (Figure S6g, h). In support of these hypotheses, FOXM1, EZH2 and 
SOX2 were all necessary for the effect of SCIRT on sphere formation for both MDA-MB-231 
(Figure 4f) and MCF-7 cells (Figure S6i), as silencing of any of these factors could prevent 
increases in sphere growth following down-regulation of SCIRT (Figure 4f and Figure S6i). 
Effects seen on sphere formation appear additive for EZH2 and SOX2, suggesting they may 
act independently (Figure 4f). Additionally, we observed that the copy number of SCIRT 
transcripts per sample was similar to the copy number of EZH2 or SOX2 mRNAs (Figure S6j: i, 
ii and iii), indicating that they reach stoichiometric ratios and that SCIRT is an abundant 
lncRNA able to interact with several genomic regions together with these factors. To assess 
this effect at the gene level, we performed ChIP-seq for EZH2 and SOX2 in spheres, re-
analyzing publicly available ChIP-seq data for FOXM1 (GSE40762) as well as H3K4me1 and 
H3K4me3 (GSE124379) from MDA-MB-231 cells and integrating these data with our SCIRT-
CHART-seq and our ChIP-seq from H3K27me3. K-means clustering of these peaks indicated 
that SCIRT, FOXM1, EZH2 and SOX2 mostly colocalize close to TSSs of a fraction of genes 
regulated by SCIRT (Figure 5a). However, SOX2 and EZH2 colocalized with SCIRT at 
promoters of genes up-regulated upon siSCIRT treatment, as anticipated (Figure 5b, c and 
Figure S6a), but surprisingly also at promoters of cell-cycle genes down-regulated upon 
SCIRT knockdown together with FOXM1 (Figure 5b, d and Figure S6b). Intriguingly, this 
indicates that in addition to activating genes involved in self-renewal (5) (Figure S6g), SOX2 
can also regulate the transcription of cell-cycle genes that are targets of FOXM1 and SCIRT 
during sphere formation. In line with this, depleting SOX2 using siRNAs (siSOX2) increased 
the expression of a set of genes involved in cell-cycle (Figure 5e), which are also increased 
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by siEZH2 (Figure S6f) but reduced by both siSCIRT and siFOXM1 (Figure 6f, Figure S6e and 
Supplementary Table 3). As expected, genes increased by siSCIRT (Supplementary Table 3) 
were down-regulated by siSOX2 and siEZH2 (Figure S6g, h). In aggregate, these data suggest 
that SCIRT, EZH2 and SOX2 colocalize at promoters of their target genes but that SCIRT 
antagonizes EZH2 and SOX2 in the transcriptional regulation of those genes.  
In embryonic stem cells, the PRC2 complex and consequently H3K27me3, colocalize at 
promoters of developmental regulators with the pluripotency TFs SOX2, NANOG and OCT4 
(38). Importantly, in mammals, PRC2 is enriched at genomic regions with high GC content, 
which are enriched with CpG islands (39). By applying K-means clustering in CHART-seq and 
ChIP-seq peaks at promoters of SCIRT regulated genes we showed that EZH2 and SOX2 
colocalize next to SCIRT peaks and exactly on CpG islands (CGIs) (Figure S7a). However, 
these two proteins not only colocalized within promoters of genes regulated by SCIRT or 
CGIs but much more broadly at multiple locations with high GC content, (Figure S7b and 
Figure S8a, b). Accordingly, SOX2 and EZH2 global binding profiles showed a striking positive 
correlation of R2=0.91 (Spearman's rank correlation, Figure S7b), and both TFs showed a 
strong positive correlation with GC% (Figure S8b; EZH2~GC% = 0.86; SOX2~GC% = 0.77).  
SCIRT increases cell cycle gene expression by binding EZH2 to induce EZH2-FOXM1 
interaction within promoters 
By specifically looking at promoters of genes regulated by SCIRT, and by sorting regions for 
up- and down-regulated genes, we found that FOXM1 mostly colocalized with SCIRT on 
promoters of genes down-regulated by siSCIRT, that are enriched for cell-cycle and have a 
CHR motif (Figure 5b). Importantly, promoters bound to FOXM1 and SCIRT were strongly 
depleted of H3K27me3 signal (Figure 5b and Figure S8), indicating that the 
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SCIRT/FOXM1/EZH2 acts on gene transcription independently of PRC2 activity. Further 
supporting this, the promoter of CCNA2, a direct target of both FOXM1 and SCIRT (Figure 
S8b and Supplementary Table 3), was enriched for EZH2 but not by SUZ12 binding (Figure 
S9a). These data also indicate that in spheres, EZH2 activity is Polycomb-independent, 
regulating a subset of genes that are directly controlled by SCIRT/FOXM1/EZH2.  
Interestingly, RIP-RT-qPCR for SCIRT after using an antibody against FOXM1 indicates that 
FOXM1 also interacts with SCIRT (Figure S9b), but, suppression of FOXM1 did not reduce 
EZH2 binding with SCIRT (Figure 6a). When we performed RIP after UV crosslinking (X_RIP), 
which only detects direct RNA-protein interactions, we found that only EZH2, not FOXM1, 
was able to form an RNA-protein complex with SCIRT (Figure S9c, d) indicating that FOXM1 
binds to SCIRT indirectly. Next, by using co-IP, we found that FOXM1 physically interacted 
with EZH2 in spheres formed by MCF-7 or MDA-MB-231 (Figure 6b), but depletion of SCIRT 
completely disrupted this interaction (Figure 6c left and right panels).  
Mechanistically, although siSCIRT treatment for 48h did not affect FOXM1 protein levels 
(Figure 6d), it reduced FOXM1 (Figure 6e) as well as Pol II and H3K27ac levels at promoters 
of cell-cycle genes (Figure S10a, b). The effect of siSCIRT on FOXM1 recruitment at cell-cycle 
gene promoters was stronger in MDA-MB-231 than MCF-7 cells (Figure 6e). This is likely due 
to the higher expression levels of SCIRT in MDA-MB-231 compared to MCF-7. This suggested 
that cell-cycle genes are repressed by EZH2 (Figure S6f), but that SCIRT activates their 
transcription by recruiting FOXM1, Pol II and histone acetyltransferases to promoters of cell-
cycle genes to counteract the slow proliferation of spheres, and induce differentiation. In 
aggregate, we revealed that SCIRT interacts with EZH2 to promote EZH2-FOXM1 protein-
protein interactions at promoters of cell-cycle genes to constrain the transcriptional 
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repression exerted by EZH2 on these genes. This fine-tunes their expression during TIC 
formation.  
Because these genes are repressed during TIC formation whereas SCIRT is up-regulated, 
SCIRT acts in a negative feedback loop to attenuate this transcriptional response. 
Single-cell RNA-seq analysis shows SCIRT is mostly present in primary breast cancer cells 
that express pluripotent TFs 
Our results point to the role of SCIRT in counteracting stemness of TICs. It is thought that 
TICs are aggressive self-renewing tumor cells that are controlled by pluripotent TFs (40). To 
evaluate whether SCIRT is co-expressed with pluripotency TFs in breast cancer cells we re-
analyzed a public single-cell RNA-seq (scRNA-seq) study (GSE75688) performed in 515 cells 
isolated from 11 primary human breast cancer cells and representing all the 4 breast cancer 
subtypes (Luminal A, Luminal B, HER2+ and TNBC) (41) (Figure S11). We identified two 
different HER2+ subtypes that cluster with two different patients (cluster 1 and 6, Figure 
S11a) and cluster 6 had SOX2 as discriminative marker (Figure S11b, c and Supplementary 
Table 6, p-adjusted < 0.01). Interestingly, the HER2+ breast cancer subtype represented by 
cluster 6 (Figure S11a), contained the highest proportion of cells expressing SCIRT and SCIRT 
was not expressed in stromal cells (Figure S11b, c). In this tumor, cells expressing SCIRT 
were fewer (20%) but had a similar average expression levels than SOX2 (Figure S11c), 
indicating that both can reach stoichiometric ratio in primary tumor cells as well as in cell 
lines. These data indicated that this HER2+ subtype that has cells with high levels of SCIRT is 
less differentiated than the second (cluster 1) and probably more aggressive. In line with 
this hypothesis, this HER2+ subtype had also a high expression of additional pluripotent TFs, 
such as KLF4, EZH2 as well as ZNF217 which are strongly involved in breast cancer stemness 
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(22) (Figure S11b, c) in addition to SOX2. Finally, specific gene markers that characterize this 
tumor (Supplementary Table 6, p-adjusted < 0.01) were mostly regulated by ZNF217, SOX2 
and FOXM1 transcription factors (Figure S11d) confirming that SCIRT is more expressed in 
less differentiated/more aggressive tumors. POU5F1 that encodes for OCT4 was only 
detected in a very small number of cells (Figure S11b,c), despite its documented role in 
breast cancer stemness and tumorigenesis (42), probably because its expression levels are 
mostly below the limit of detection of this scRNA-seq experiment.  
SCIRT is up-regulated in breast cancer specimens but its high expression is associated with 
good prognosis 
Next, we evaluated the clinical significance of this SCIRT-controlled transcriptional 
regulatory network. We first measured SCIRT, FOXM1, EZH2 and SOX2 expression from RNA-
seq data obtained from 1391 specimens from the TCGA and GTEx cohorts and related 
expression levels of these genes to available TCGA clinical data. Similar to FOXM1 and EZH2, 
SCIRT was significantly more expressed in breast cancers compared to normal tissues 
(Welch's t-test, p < 2.2e-16) (Figure S12 a-c) and showed the highest expression levels in the 
basal and Her2+ subtypes which represent more aggressive tumor types (Figure S12d-f). We 
observed similar trends in cells derived from primary tumors (Figure 2a and Figure S11b, c). 
However, differences detected for both FOXM1 and EZH2 were generally more dramatic 
and less variable than those observed for SCIRT (Figure S12a-f). Surprisingly, SOX2 levels 
showed a different pattern of expression in breast cancers compared to SCIRT, FOXM1 and 
EZH2 (Figure S12 g), suggesting that the role of SOX2 in SCIRT/EZH2/FOXM1 regulatory 
network is context-specific and can occur only in rarer TICs. In general, SCIRT levels 
correlated positively with both EZH2 and FOXM1 (Figure S13a, b) but did not correlate with 
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SOX2 in either cancer or normal samples (Figure S13c). However, FOXM1 correlated better 
with EZH2 than SOX2 (Figure S13d, e). 
Strikingly, while high expression levels of FOXM1 and EZH2 were associated with worse 
disease-free survival (DFS), high expression levels of SCIRT were associated with better DFS 
(Figure S14a). These results are in line with our findings: that SCIRT is co-expressed and co-
regulates gene expression with oncogenic EZH2 and FOXM1 but, in the opposite direction, 
restraining tumorigenesis if up-regulated in tumorigenic cells.  
Next, anticipating  that genes that are repressed by SCIRT (up-regulated by siSCIRT) are  
oncogenic, we selected the top 100 genes with greatest up-regulation upon depletion of 
SCIRT by 2 independent siRNAs (Supplementary Table 7) and evaluated their expression 
levels, clinical relevance and mutational landscape in both the TCGA (43) and the METABRIC 
breast cancer datasets (44) interrogating a total of 3334 breast cancer samples (Figure 
S14b). These genes were up-regulated in almost all breast cancer specimens (Figure S14c), 
probably due to genome amplification at the genomic loci containing these genes (Figure 
S14d). Finally, breast cancer samples presenting amplification in these loci (Figure S14e) and 
samples with high expression of these genes (Figure S14f) presented worse overall survival.  
In summary, we describe a novel lncRNA named SCIRT to be up-regulated in TICs in breast 
cancer but to counteract tumorigenesis despite its increased expression. This suggests that 
re-expression of SCIRT or inhibition of genes that are strongly repressed by SCIRT (Figure 
S14b) in patients, could represent a useful therapeutic approach to tackle the dynamic 
process of TIC self-renewal and differentiation in breast cancer. We also find that genes 
repressed by SCIRT are frequently amplified in breast cancer. Taken together this gene set 
SCIRT is a novel lncRNA that regulates cancer stemness 
24 
 
can be used as a novel signature to stratify the disease with diagnostic and prognostic 
implications.  
Discussion 
Using an lncRNA that we describe for the first time, SCIRT, we expand our understanding of 
the transcriptional regulation of stemness and proliferative expression programs active in 
breast TICs. EZH2 and SOX2 are transcription factors able to increase self-renewal capacity 
of both embryonic stem cells and cancer stem cells (6,45,46). By using a breast cancer 
tumorsphere formation assay, which enriches for slow-proliferating cancer stem cells or 
TICs, we observed that these two factors widely colocalize within CG-rich chromatin regions, 
including CpG islands located within promoters and when they interact with specific 
promoters, they repress cell-cycle gene expression and activate self-renewal and neuronal 
gene programs in breast cancer cells that grow in 3D conditions, indicating that SOX2 and 
EZH2 are also crucial factors that instruct TICs to proliferate slowly.  
We further observed that this transcriptional program regulated by SOX2 and EZH2 in breast 
tumor does not occur unopposed but it is counteracted by SCIRT, strongly up-regulated 
during tumorsphere formation, but unexpectedly, functioning by counteracting EZH2 and 
SOX2's effects on the transcription of many self-renewal and cell cycle genes. By acting in 
this negative feedback loop, SCIRT increases cell-cycle and represses self-renewal 
transcriptional programs of these cells (Figure S15). Our data are in line with the hypothesis 
that SCIRT acts as a regulator that only reduces transcription of genes involved in 
tumorigenesis without fully repressing their activity. In this manner SCIRT tends to be more 
expressed in tumors than normal cells, but when it is expressed is associated with a more 
favorable prognosis.  
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We show for the first time that during sphere growth EZH2 binds to cell-cycle gene 
promoters to act as a co-repressor with its binding partner FOXM1, restraining its effects on 
transcription. SCIRT directly interacts with EZH2 to increase EZH2-FOXM1 interaction and 
recruit more FOXM1 to promoters to fine-tune this cell-cycle transcriptional program (Figure 
S15). Previously, it was reported that FOXM1 and EZH2 interact during hypoxia in breast 
cancer to activate MMP2 and MMP7 transcription (47), suggesting that SCIRT may mediate 
the interaction between FOXM1 and EZH2 and their transcriptional effects during hypoxia as 
well. However, to the best of our knowledge, the importance of the EZH2-FOXM1 
antagonistic interaction for the regulation of cell-cycle gene transcription has not been 
described elsewhere. Our results suggest that this effect mediated by SCIRT is specifically 
related to an EZH2-FOXM1 interaction which seems to be independent of the PRC2 
complex. When selected lncRNAs interact with EZH2, it appears they may change EZH2's 
affinity for its protein binding partners. It would be interesting to evaluate whether the 
binding of selected lncRNAs to EZH2 also changes PRC2 complex composition and activity 
rather than its recruitment to chromatin as widely described, or whether this action may be 
mediated by SCIRT alone in other cellular contexts.  
Unexpectedly, we also found that SOX2, a TF that promotes self-renewal gene expression in 
TICs (5), also colocalized with EZH2 on promoters of cell-cycle genes to repress their 
transcription. Yet transcription from these promoters occurs during sphere growth, due to 
the dominant effects of SCIRT and FOXM1. Supporting this novel role for SOX2 in cell-cycle 
regulation, alongside its established function in TIC self-renewal, SOX2 has been reported to 
repress pro-proliferative cell-cycle genes in cortical progenitors to maintain their slow 
proliferative state (48).  
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Although we demonstrate that the interaction between FOXM1 and EZH2 is modulated by 
SCIRT, FOXM1 is mostly absent from the promoters of self-renewal genes up-regulated upon 
SCIRT depletion. We suggest that FOXM1 is not present within these genomic positions 
despite the presence of SCIRT and EZH2, because these genomic sites do not have a CHR 
motif (Figure 5b) which is the FOXM1 consensus sites essential for its DNA binding (49). 
Additionally or alternatively, a higher level of GC content or (consequently) high levels of 
EZH2/SOX2 interactions within these promoters, may prevent FOXM1's DNA binding. In 
support of this latter view, we observed FOXM1 binding site peaks in promoters of genes 
down-regulated by SCIRT that are adjacent to EZH2 and SOX2 binding sites (Figure S7a and 
Figure S8a) indicating that FOXM1 cannot interact with DNA in regions occupied by EZH2 
and SOX2, but resides next to them. As reported by others in embryonic stem cells, we did 
not find a physical interaction between EZH2-SOX2 in breast cancer, suggesting that their 
co-localization depends on DNA rather than protein-protein interaction (50).  
In aggregate, based on these data we propose that SCIRT acts as a tumor suppressor in 
breast cancer, despite appearing to be more expressed in TICs compared to their more 
differentiated counterparts and in tumors compared to healthy control tissues. Indeed, 
despite being strongly co-expressed with FOXM1 and EZH2, high expression of FOXM1 and 
EZH2 in clinical samples predicts poor DFS, but DFS is better in patients with high levels of 
SCIRT supporting the idea that SCIRT is induced in tumorigenic cells but counteracts their 
aggressive properties (Figure 2 and Figure S2e, f).  
Future cancer treatments may include TIC and differentiated cell-targeting components. 
Inducing SCIRT or SCIRT-like factors that promote differentiation towards chemotherapy-
vulnerable cell states, could enhance the success of such future approaches. 
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Figure 1 – RNA-seq from MDA-MB-231 breast cancer cells grown in 2D or 3D conditions 
identify the change in lncRNA expression. (a) Left. Representative images of MDA-MB-231 
cells grown in adherent (adh) and tumorspheres (spheres) conditions. Right. Heatmap 
showing expression levels of significantly up- and down-regulated genes between adh, 16h 
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and 5d spheres (R1 =replicate #1; R2 = Replicate #2). (b) Log2 fold change of lncRNA 
candidates’ expression between 16h or 5d MDA-MB-231 spheres compared to adh cells. (c) 
Percentage of sphere formation efficiency (SFE%) after down-regulation of lncRNA 
candidates in MDA-MB-231 and (d) MCF-7 cells. Results are from two independent 
experiments each performed in triplicate. n=6, * p<0.05, ** p<0.01. P-values are calculated 
using non-parametric Mann–Whitney U test. 
 
Figure 2 – SCIRT is chromatin-enriched, up-regulated in spheres (16h and 5d) but 
counteracts stemness. (a) Boxplots showing fold change in expression of SCIRT in spheres 
compared to adh cells isolated from luminal A and basal breast cancer patient tumors. Data 
are from two independent tumors per subtype each plated in triplicates; n=6, ** p<0.01. (b) 
Barplots showing SFE% in the first and second generation after down-regulation of SCIRT 
with two independent siRNAs (siSCIRT#1 or siSCIRT#2) in breast cancer cell lines MDA-MB-
231 and MCF-7. Results are from two independent experiments each performed in 
triplicate. n=6, * p<0.05, ** p<0.01, ns=not significant. (c) In vivo tumorigenicity assay using 
MDA-MB-231 cells stable knockdown for lncRNA SCIRT (shSCIRT) or control cells (shNC) 
injected subcutaneously in immunocompromised, nude mice. Tumor take frequency is 
shown in the upper panel. Images of resected tumors are shown in the middle panel. Tumor 
growth during 48 days of monitoring is present in the lower panel. (d) Images of RNA FISH 
experiments with probes for lncRNA SCIRT in MCF-7 cells treated with siSCIRT or siNC. (e) 
RT-qPCR values showing the expression of SCIRT, MALAT1 and GAPDH in different cellular 
fractions of MDA-MB-231 sphere derived cells. The values are from two independent 
experiments and are expressed as fold change to free nuclear fraction. P-values are 
calculated using non-parametric Mann–Whitney U test. 




Figure 3 – SCIRT specifically interacts with cis-regulatory regions to down-regulate 
stemness genes and up-regulate cell cycle genes. (a) GSEA analysis for top enriched 
pathways for genes up- and down-regulated by siSCIRT. (b) Specific enrichment of SCIRT 
using oligonucleotides complementary to accessible regions of SCIRT compared to LacZ or 
mock control samples. (c) SCIRT binding within promoters of two genes significantly down-
regulated by siSCIRT (PRR11 and NEK2) and two genes significantly up-regulated by siSCIRT 
(SOX4 and BSDC1). (d) Top. Venn diagram showing the overlap of genes containing SCIRT 
peaks within cis-regulatory regions (+200 kb from TSSs) of genes significantly up or down-
regulated after siSCIRT. Bottom-left. Enrichment of pathways (top) and TF factor binding 
(ChEA) (bottom) analyzes performed by using Enrichr 
(https://amp.pharm.mssm.edu/Enrichr/) for genes bound by SCIRT and down-regulated 
after siSCIRT#1 and #2 treatment. Bottom-right. Enrichment of pathways (top) and TF factor 
binding (ChEA) (bottom) analyzes performed by using Enricher 
(https://amp.pharm.mssm.edu/Enrichr/) for genes bound by SCIRT and up-regulated after 
siSCIRT#1 and #2 treatment. 
 
Figure 4 – SCIRT interacts with EZH2 to antagonize its Polycomb-independent activity. (a) 
Venn diagram showing the overlap of genes significantly down-regulated after SCIRT 
knockdown and up-regulated after EZH2 knockdown. Enrichr ChEA analysis shows FOXM1 
and E2F4 TF are enriched and bind to genes from the overlap. (b) Venn diagram showing the 
overlap of genes significantly up-regulated after silencing SCIRT and genes significantly 
down-regulated after silencing EZH2. Enrichr ChEA analysis shows SOX2 TF is enriched and 
binds to genes from the overlap. (c) Representation of H3K27me3 occupancy from ChIP-seq 
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data of siNC, siEZH2 and siSCIRT treated MDA-MB-231 spheres at expressed and repressed 
genes. (d) Representation of H3K27me3 occupancy from ChIP-seq data of MDA-MB-231 
spheres treated with siNC, siEZH2 and siSCIRT at genes down-regulated after silencing 
SCIRT. (e) Representation of H3K27me3 occupancy from ChIP-seq data of MDA-MB-231 
spheres treated with siNC, siEZH2 and siSCIRT at genes up-regulated after silencing SCIRT. (f) 
Barplots show sphere formation efficiency after siRNA down-regulation of SCIRT, FOXM1 
and SCIRT/FOXM1 co-repression; SCIRT, SOX2 and SCIRT/SOX2 co-repression; SCIRT, EZH2 
and SCIRT/EZH2 co-repression in MDA-MB-231 cells. Spheres were counted at day 5 from 
siRNA transfection and the results are from two independent experiments each performed 
in duplicate. n=4, * p<0.05; ns=not significant. P-values were calculated using non-
parametric Mann–Whitney U test. 
Figure 5 – SCIRT colocalizes with EZH2, FOXM1 and SOX2 at promoters of regulated genes. 
(a) Left. Heatmap and K-mean clustering of genomic regions occupied by H3K4me1, 
H3K4me3, FOXM1, EZH2 and SOX2 within SCIRT peaks associated with SCIRT-regulated 
genes. These regions were not occupied by LacZ used as negative control. Right. Bar-plot 
depicting the number of genes from the top cluster in the heatmap, associated with 
promoters or distant sites (b) Heatmap generated from each replicate pairs from CHART-seq 
(LacZ and SCIRT) and ChIP-seq (SOX2, EZH2, H3K27me3) experiments and publicly available 
FOXM1 (GSE40762) ChIP-seq data. Enriched known TF motif in SCIRT peaks were obtained 
using HOMER (c). Average of normalized peak density of SCIRT, EZH2 and SOX2 around TSSs 
of genes up-regulated or (d) down-regulated by siSCIRT treatment. (e) Barplots showing 
expression changes of a subset of genes up-regulated by siSCIRT, upon siSOX2 (right 
treatment compared to siNC treatment. Data derive from two independent experiments 
SCIRT is a novel lncRNA that regulates cancer stemness 
34 
 
each performed in duplicate; n=4, * p<0.05. P-values are calculated using non-parametric 
Mann–Whitney U test.  
 
Figure 6 – SCIRT interacts with FOXM1 and is important for FOXM1 recruitment on cell 
cycle genes. (a) RNA-immunoprecipitation (RIP) followed by RT-qPCR shows that SCIRT 
interacts with EZH2, but FOXM1 does not modulate this interaction. Data shown are from 
two independent experiments, n=2. U1 snRNA and IgG were used as negative controls. (b) 
Co-IP assay shows a physical interaction between EZH2 and FOXM1 in MDA-MB-231 
spheres. (c) Co-IP assay obtained by immunoprecipitation of EZH2 (left panel) or FOXM1 
(right panel) shows that SCIRT depletion disrupts the interaction between EZH2 and FOXM1 
in MDA-MB-231 spheres. (d) Western blot showing that the level of FOXM1 protein remains 
unchanged in the cells where SCIRT is transiently down-regulated. (e) FOXM1 chromatin-
immunoprecipitation (ChIP) followed by qPCR shows that FOXM1 binding on mitotic genes is 
reduced after SCIRT down-regulation in spheres. Data are from two independent 
experiments each performed in duplicate (MDA-MB-231, n=2; MCF-7, n=4). * p<0.05, ** 
p<0.01, *** p<0.001. P-values are calculated using t-test (f) Left panel: Venn diagram 
showing overlap between genes significantly down-regulated by SCIRT siRNA (siSCIRT) (p-
adjusted-value < 0.05) with genes significantly down-regulated by FOXM1 (siFOXM1) (p-
adjusted-value < 0.05) in MDA-MB-231 cells. Right panel: GO-term enriched analysis 
performed by using Enrichr of genes significantly down-regulated by siSCIRT (2 independent 
siRNAs) only (top), by both siSCIRT and siFOXM1 (middle) and siFOXM1 only (bottom).  
 






